Brian Druker

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Physiology

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
O'Hare Thomas; Shakespeare William C; Zhu Xiaotian; Eide Christopher A; Rivera Victor M; Wang Frank; Adrian Lauren T; Zhou Tianjun; Huang Wei-Sheng; Xu Qihong; Metcalf Chester A; Tyner Jeffrey W; Loriaux Marc M; Corbin Amie S; Wardwell Scott; Ning Yaoyu; Keats Jeffrey A; Wang Yihan; Sundaramoorthi Raji; Thomas Mathew; Zhou Dong; Snodgrass Joseph; Commodore Lois; Sawyer Tomi K; Dalgarno David C; Deininger Michael W N; Druker Brian J; Clackson Tim
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Druker Brian J
Perspectives on the development of imatinib and the future of cancer research.
Snead Jennifer L; O'Hare Thomas; Adrian Lauren T; Eide Christopher A; Lange Thoralf; Druker Brian J; Deininger Michael W
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Brian Druker (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: O'Hare Thomas; Shakespeare William C; Zhu Xiaotian; Eide Christopher A; Rivera Victor M; Wang Frank; Adrian Lauren T; Zhou Tianjun; Huang Wei-Sheng; Xu Qihong; Metcalf Chester A; Tyner Jeffrey W; Loriaux Marc M; Corbin Amie S; Wardwell Scott; Ning Yaoyu; Keats Jeffrey A; Wang Yihan; Sundaramoorthi Raji; Thomas Mathew; Zhou Dong; Snodgrass Joseph; Commodore Lois; Sawyer Tomi K; Dalgarno David C; Deininger Michael W N; Druker Brian J; Clackson Tim
AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance.
Cancer cell 2009;16(5):401-12.
2009: Druker Brian J
Perspectives on the development of imatinib and the future of cancer research.
Nature medicine 2009;15(10):1149-52.
2009: Snead Jennifer L; O'Hare Thomas; Adrian Lauren T; Eide Christopher A; Lange Thoralf; Druker Brian J; Deininger Michael W
Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis.
Blood 2009;114(16):3459-63.
2009: Tyner Jeffrey; Druker Brian J
RNAi screen for therapeutic target in leukemia.
Cell cycle (Georgetown, Tex.) 2009;8(14):2144.
2009: Tyner J W; Rutenberg-Schoenberg M L; Erickson H; Willis S G; O'Hare T; Deininger M W; Druker B J; Loriaux M M
Functional characterization of an activating TEK mutation in acute myeloid leukemia: a cellular context-dependent activating mutation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(7):1345-8.
2009: Scholl Benjamin; Liu Hong Yan; Long Brian R; McCarty Owen J T; O'Hare Thomas; Druker Brian J; Vu Tania Q
Single particle quantum dot imaging achieves ultrasensitive detection capabilities for Western immunoblot analysis.
ACS nano 2009;3(6):1318-28.
2009: Hochhaus A; O'Brien S G; Guilhot F; Druker B J; Branford S; Foroni L; Goldman J M; Müller M C; Radich J P; Rudoltz M; Mone M; Gathmann I; Hughes T P; Larson R A;
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(6):1054-61.
2009: Tyner Jeffrey W; Deininger Michael W; Loriaux Marc M; Chang Bill H; Gotlib Jason R; Willis Stephanie G; Erickson Heidi; Kovacsovics Tibor; O'Hare Thomas; Heinrich Michael C; Druker Brian J
RNAi screen for rapid therapeutic target identification in leukemia patients.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(21):8695-700.
2009: Kantarjian Hagop M; Larson Richard A; Guilhot Francois; O'Brien Stephen G; Mone Manisha; Rudoltz Marc; Krahnke Tillmann; Cortes Jorge; Druker Brian J;
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
Cancer 2009;115(3):551-60.
2009: Tyner Jeffrey W; Erickson Heidi; Deininger Michael W N; Willis Stephanie G; Eide Christopher A; Levine Ross L; Heinrich Michael C; Gattermann Norbert; Gilliland D Gary; Druker Brian J; Loriaux Marc M
High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients.
Blood 2009;113(8):1749-55.
2009: Tyner J W; Loriaux M M; Erickson H; Eide C A; Deininger J; MacPartlin M; Willis S G; Lange T; Druker B J; Kovacsovics T; Maziarz R; Gattermann N; Deininger M W
High-throughput mutational screen of the tyrosine kinome in chronic myelomonocytic leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(2):406-9.
2009: Johnson Kara J; Griswold Ian J; O'Hare Thomas; Corbin Amie S; Loriaux Marc; Deininger Michael W; Druker Brian J
A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.
PloS one 2009;4(10):e7439.
2008: Druker Brian J
Translation of the Philadelphia chromosome into therapy for CML.
Blood 2008;112(13):4808-17.
2008: Agarwal A; Eide C A; Harlow A; Corbin A S; Mauro M J; Druker B J; Corless C L; Heinrich M C; Deininger M W
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(12):2269-72.
2008: Zhang Min; Fu Wuxia; Prabhu Sharmila; Moore James C; Ko Je; Kim Jung Woo; Druker Brian J; Trapp Valerie; Fruehauf John; Gram Hermann; Fan Hung Y; Ong S Tiong
Inhibition of polysome assembly enhances imatinib activity against chronic myelogenous leukemia and overcomes imatinib resistance.
Molecular and cellular biology 2008;28(20):6496-509.
2008: Agarwal Anupriya; Bumm Thomas G P; Corbin Amie S; O'Hare Thomas; Loriaux Marc; VanDyke Jonathan; Willis Stephanie G; Deininger Jutta; Nakayama Keiichi I; Druker Brian J; Deininger Michael W
Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Blood 2008;112(5):1960-70.
2008: MacPartlin M; Smith A M; Druker B J; Honigberg L A; Deininger M W
Bruton's tyrosine kinase is not essential for Bcr-Abl-mediated transformation of lymphoid or myeloid cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(7):1354-60.
2008: Sherbenou D W; Hantschel O; Turaga L; Kaupe I; Willis S; Bumm T; Press R D; Superti-Furga G; Druker B J; Deininger M W
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2008;22(6):1184-90.
2008: Loriaux Marc M; Levine Ross L; Tyner Jeffrey W; Fröhling Stefan; Scholl Claudia; Stoffregen Eric P; Wernig Gerlinde; Erickson Heidi; Eide Christopher A; Berger Roland; Bernard Olivier A; Griffin James D; Stone Richard M; Lee Benjamin; Meyerson Matthew; Heinrich Michael C; Deininger Michael W; Gilliland D Gary; Druker Brian J
High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.
Blood 2008;111(9):4788-96.
2008: Katsoulidis Efstratios; Sassano Antonella; Majchrzak-Kita Beata; Carayol Nathalie; Yoon Patrick; Jordan Alison; Druker Brian J; Fish Eleanor N; Platanias Leonidas C
Suppression of interferon (IFN)-inducible genes and IFN-mediated functional responses in BCR-ABL-expressing cells.
The Journal of biological chemistry 2008;283(16):10793-803.
2008: Larson Richard A; Druker Brian J; Guilhot Francois; O'Brien Stephen G; Riviere Gilles J; Krahnke Tillmann; Gathmann Insa; Wang Yanfeng;
Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.
Blood 2008;111(8):4022-8.
2008: Laudadio Jennifer; Deininger Michael W N; Mauro Michael J; Druker Brian J; Press Richard D
An intron-derived insertion/truncation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.
The Journal of molecular diagnostics : JMD 2008;10(2):177-80.
2008: Carayol Nathalie; Katsoulidis Efstratios; Sassano Antonella; Altman Jessica K; Druker Brian J; Platanias Leonidas C
Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway.
The Journal of biological chemistry 2008;283(13):8601-10.
2008: Tyner Jeffrey W; Walters Denise K; Willis Stephanie G; Luttropp Mary; Oost Jason; Loriaux Marc; Erickson Heidi; Corbin Amie S; O'Hare Thomas; Heinrich Michael C; Deininger Michael W; Druker Brian J
RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.
Blood 2008;111(4):2238-45.
2008: Hochhaus Andreas; Druker Brian; Sawyers Charles; Guilhot Francois; Schiffer Charles A; Cortes Jorge; Niederwieser Dietger W; Gambacorti-Passerini Carlo; Stone Richard M; Goldman John; Fischer Thomas; O'Brien Stephen G; Reiffers Jose J; Mone Manisha; Krahnke Tillmann; Talpaz Moshe; Kantarjian Hagop M
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment.
Blood 2008;111(3):1039-43.
2008: Chou C James; O'Hare Thomas; Lefebvre Sophie; Alvarez David; Tyner Jeffrey W; Eide Christopher A; Druker Brian J; Gottesfeld Joel M
Growth arrest of BCR-ABL positive cells with a sequence-specific polyamide-chlorambucil conjugate.
PloS one 2008;3(10):e3593.
2008: Elsea Collin R; Roberts Daniel A; Druker Brian J; Wood Lisa J
Inhibition of p38 MAPK suppresses inflammatory cytokine induction by etoposide, 5-fluorouracil, and doxorubicin without affecting tumoricidal activity.
PloS one 2008;3(6):e2355.
2007: Fröhling Stefan; Scholl Claudia; Levine Ross L; Loriaux Marc; Boggon Titus J; Bernard Olivier A; Berger Roland; Döhner Hartmut; Döhner Konstanze; Ebert Benjamin L; Teckie Sewit; Golub Todd R; Jiang Jingrui; Schittenhelm Marcus M; Lee Benjamin H; Griffin James D; Stone Richard M; Heinrich Michael C; Deininger Michael W; Druker Brian J; Gilliland D Gary
Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.
Cancer cell 2007;12(6):501-13.
2007: Chen Yunhao; Choong Lee-Yee; Lin Qingsong; Philp Robin; Wong Chee-Hong; Ang Boon-Keong; Tan Yee-Ling; Loh Marie-Chiew-Shia; Hew Choy-Leong; Shah Nilesh; Druker Brian J; Chong Poh-Kuan; Lim Yoon-Pin
Differential expression of novel tyrosine kinase substrates during breast cancer development.
Molecular & cellular proteomics : MCP 2007;6(12):2072-87.
2007: Thomas Emily K; Cancelas Jose A; Chae Hee-Don; Cox Adrienne D; Keller Patricia J; Perrotti Danilo; Neviani Paolo; Druker Brian J; Setchell Kenneth D R; Zheng Yi; Harris Chad E; Williams David A
Rac guanosine triphosphatases represent integrating molecular therapeutic targets for BCR-ABL-induced myeloproliferative disease.
Cancer cell 2007;12(5):467-78.
2007: Choong Lee-Yee; Lim Simin; Loh Marie Chiew-Shia; Man Xiaohui; Chen Yunhao; Toy Weiyi; Pan Mengfei; Chen Chien-Shing; Poonepalli Anuradha; Hande M Prakash; Tan Puay-Hoon; Salto-Tellez Manuel; Wong Chow-Yin; Shah Nilesh; Druker Brian J; Lim Yoon-Pin
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics.
Molecular cancer therapeutics 2007;6(11):2828-42.
2007: Press Richard D; Galderisi Chad; Yang Rui; Rempfer Carole; Willis Stephanie G; Mauro Michael J; Druker Brian J; Deininger Michael W N
A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(20):6136-43.
2007: Deininger Michael W N; Cortes Jorge; Paquette Ron; Park Byung; Hochhaus Andreas; Baccarani Michele; Stone Richard; Fischer Thomas; Kantarjian Hagop; Niederwieser Dietger; Gambacorti-Passerini Carlo; So Charlene; Gathmann Insa; Goldman John M; Smith Douglas; Druker Brian J; Guilhot François
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells.
Cancer 2007;110(7):1509-19.
2007: Reddi Alagarsamy Lakku; Ying GuoGuang; Duan Lei; Chen Gengsheng; Dimri Manjari; Douillard Patrice; Druker Brian J; Naramura Mayumi; Band Vimla; Band Hamid
Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation.
The Journal of biological chemistry 2007;282(40):29336-47.
2007: Neviani Paolo; Santhanam Ramasamy; Oaks Joshua J; Eiring Anna M; Notari Mario; Blaser Bradley W; Liu Shujun; Trotta Rossana; Muthusamy Natarajan; Gambacorti-Passerini Carlo; Druker Brian J; Cortes Jorge; Marcucci Guido; Chen Ching-Shih; Verrills Nicole M; Roy Denis C; Caligiuri Michael A; Bloomfield Clara D; Byrd John C; Perrotti Danilo
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
The Journal of clinical investigation 2007;117(9):2408-21.
2007: Blasdel Carolyn; Egorin Merrill J; Lagattuta Theodore F; Druker Brian J; Deininger Michael W
Therapeutic drug monitoring in CML patients on imatinib.
Blood 2007;110(5):1699-701; author reply 1701.
2007: Sherbenou Daniel W; Druker Brian J
Applying the discovery of the Philadelphia chromosome.
The Journal of clinical investigation 2007;117(8):2067-74.
2007: Chen Yunhao; Low Teck-Yew; Choong Lee-Yee; Ray Rajarshi Sankar; Tan Yee-Ling; Toy Weiyi; Lin Qingsong; Ang Boon Keong; Wong Chee Hong; Lim Simin; Li Bin; Hew Choy-Leong; Sze Newman Siu-Kwan; Druker Brian J; Lim Yoon-Pin
Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells.
Proteomics 2007;7(14):2384-97.
2007: Gu Ting-lei; Mercher Thomas; Tyner Jeffrey W; Goss Valerie L; Walters Denise K; Cornejo Melanie G; Reeves Cynthia; Popova Lana; Lee Kimberly; Heinrich Michael C; Rush John; Daibata Masanori; Miyoshi Isao; Gilliland D Gary; Druker Brian J; Polakiewicz Roberto D
A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.
Blood 2007;110(1):323-33.
2007: Sherbenou D W; Wong M J; Humayun A; McGreevey L S; Harrell P; Yang R; Mauro M; Heinrich M C; Press R D; Druker B J; Deininger M W
Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2007;21(3):489-93.
2007: Hochhaus Andreas; Kantarjian Hagop M; Baccarani Michele; Lipton Jeffrey H; Apperley Jane F; Druker Brian J; Facon Thierry; Goldberg Stuart L; Cervantes Francisco; Niederwieser Dietger; Silver Richard T; Stone Richard M; Hughes Timothy P; Muller Martin C; Ezzeddine Rana; Countouriotis Athena M; Shah Neil P
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy.
Blood 2007;109(6):2303-9.
2007: Chen Jing; Yu Wen-Mei; Daino Hanako; Broxmeyer Hal E; Druker Brian J; Qu Cheng-Kui
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl.
Blood 2007;109(2):778-85.
2006: Druker Brian J; Guilhot François; O'Brien Stephen G; Gathmann Insa; Kantarjian Hagop; Gattermann Norbert; Deininger Michael W N; Silver Richard T; Goldman John M; Stone Richard M; Cervantes Francisco; Hochhaus Andreas; Powell Bayard L; Gabrilove Janice L; Rousselot Philippe; Reiffers Josy; Cornelissen Jan J; Hughes Timothy; Agis Hermine; Fischer Thomas; Verhoef Gregor; Shepherd John; Saglio Giuseppe; Gratwohl Alois; Nielsen Johan L; Radich Jerald P; Simonsson Bengt; Taylor Kerry; Baccarani Michele; So Charlene; Letvak Laurie; Larson Richard A;
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
The New England journal of medicine 2006;355(23):2408-17.
2006: Bumm Thomas G P; Elsea Collin; Corbin Amie S; Loriaux Marc; Sherbenou Daniel; Wood Lisa; Deininger Jutta; Silver Richard T; Druker Brian J; Deininger Michael W N
Characterization of murine JAK2V617F-positive myeloproliferative disease.
Cancer research 2006;66(23):11156-65.
2006: Gu Ting-Lei; Goss Valerie L; Reeves Cynthia; Popova Lana; Nardone Julie; Macneill Joan; Walters Denise K; Wang Yi; Rush John; Comb Michael J; Druker Brian J; Polakiewicz Roberto D
Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia.
Blood 2006;108(13):4202-4.
2006: DeAngelo Daniel J; Stone Richard M; Heaney Mark L; Nimer Stephen D; Paquette Ronald L; Klisovic Rebecca B; Caligiuri Michael A; Cooper Michael R; Lecerf Jean-Michel; Karol Michael D; Sheng Shihong; Holford Nick; Curtin Peter T; Druker Brian J; Heinrich Michael C
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Blood 2006;108(12):3674-81.
2006: La Rosée Paul; Jia Taiping; Demehri Shadmer; Härtel Nicolai; de Vries Peter; Bonham Lynn; Hollenback David; Singer Jack W; Melo Junia V; Druker Brian J; Deininger Michael W
Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6540-6.
2006: Wood Lisa J; Nail Lillian M; Perrin Nancy A; Elsea Collin R; Fischer April; Druker Brian J
The cancer chemotherapy drug etoposide (VP-16) induces proinflammatory cytokine production and sickness behavior-like symptoms in a mouse model of cancer chemotherapy-related symptoms.
Biological research for nursing 2006;8(2):157-69.
2006: Kuroda Junya; Puthalakath Hamsa; Cragg Mark S; Kelly Priscilla N; Bouillet Philippe; Huang David C S; Kimura Shinya; Ottmann Oliver G; Druker Brian J; Villunger Andreas; Roberts Andrew W; Strasser Andreas
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(40):14907-12.
2006: Bradeen Heather A; Eide Christopher A; O'Hare Thomas; Johnson Kara J; Willis Stephanie G; Lee Francis Y; Druker Brian J; Deininger Michael W
Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.
Blood 2006;108(7):2332-8.
2006: Roy Lydia; Guilhot Joëlle; Krahnke Tillmann; Guerci-Bresler Agnès; Druker Brian J; Larson Richard A; O'Brien Steve; So Charlene; Massimini Giorgio; Guilhot François
Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.
Blood 2006;108(5):1478-84.
2006: Walters Denise K; Goss Valerie L; Stoffregen Eric P; Gu Ting-Lei; Lee Kimberly; Nardone Julie; McGreevey Laura; Heinrich Michael C; Deininger Michael W; Polakiewicz Roberto; Druker Brian J
Phosphoproteomic analysis of AML cell lines identifies leukemic oncogenes.
Leukemia research 2006;30(9):1097-104.
2006: Griswold Ian J; MacPartlin Mary; Bumm Thomas; Goss Valerie L; O'Hare Thomas; Lee Kimberly A; Corbin Amie S; Stoffregen Eric P; Smith Caitlyn; Johnson Kara; Moseson Erika M; Wood Lisa J; Polakiewicz Roberto D; Druker Brian J; Deininger Michael W
Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib.
Molecular and cellular biology 2006;26(16):6082-93.
2006: Walters Denise K; Mercher Thomas; Gu Ting-Lei; O'Hare Thomas; Tyner Jeffrey W; Loriaux Marc; Goss Valerie L; Lee Kimberly A; Eide Christopher A; Wong Matthew J; Stoffregen Eric P; McGreevey Laura; Nardone Julie; Moore Sandra A; Crispino John; Boggon Titus J; Heinrich Michael C; Deininger Michael W; Polakiewicz Roberto D; Gilliland D Gary; Druker Brian J
Activating alleles of JAK3 in acute megakaryoblastic leukemia.
Cancer cell 2006;10(1):65-75.
2006: Hughes Timothy; Deininger Michael; Hochhaus Andreas; Branford Susan; Radich Jerald; Kaeda Jaspal; Baccarani Michele; Cortes Jorge; Cross Nicholas C P; Druker Brian J; Gabert Jean; Grimwade David; Hehlmann Rüdiger; Kamel-Reid Suzanne; Lipton Jeffrey H; Longtine Janina; Martinelli Giovanni; Saglio Giuseppe; Soverini Simona; Stock Wendy; Goldman John M
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Blood 2006;108(1):28-37.
2006: Druker Brian J
Circumventing resistance to kinase-inhibitor therapy.
The New England journal of medicine 2006;354(24):2594-6.
2006: Press Richard D; Love Zac; Tronnes Ashlie A; Yang Rui; Tran Thuan; Mongoue-Tchokote Solange; Mori Motomi; Mauro Michael J; Deininger Michael W; Druker Brian J
BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.
Blood 2006;107(11):4250-6.
2006: Nguyen Tri K; Rahmani Mohamed; Gao Ning; Kramer Lora; Corbin Amie S; Druker Brian J; Dent Paul; Grant Steven
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2239-47.
2006: Deininger Michael; Schleuning Michael; Greinix Hilde; Sayer Herbert Gottfried; Fischer Thomas; Martinez Jesus; Maziarz Richard; Olavarria Eduardo; Verdonck Leo; Schaefer Kerstin; Boqué Conxa; Faber Edgar; Nagler Arnon; Pogliani Enrico; Russell Nigel; Volin Liisa; Schanz Urs; Doelken Gottfried; Kiehl Michael; Fauser Axel; Druker Brian; Sureda Anna; Iacobelli Simona; Brand Ronald; Krahl Rainer; Lange Thoralf; Hochhaus Andreas; Gratwohl Alois; Kolb Hans; Niederwieser Dietger;
The effect of prior exposure to imatinib on transplant-related mortality.
Haematologica 2006;91(4):452-9.
2006: Demehri Shadmehr; Corbin Amie; Loriaux Marc; Druker Brian J; Deininger Michael W
Establishment of a murine model of aggressive systemic mastocytosis/mast cell leukemia.
Experimental hematology 2006;34(3):284-8.
2006: Radich Jerald P; Dai Hongyue; Mao Mao; Oehler Vivian; Schelter Jan; Druker Brian; Sawyers Charles; Shah Neil; Stock Wendy; Willman Cheryl L; Friend Stephen; Linsley Peter S
Gene expression changes associated with progression and response in chronic myeloid leukemia.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(8):2794-9.
2006: O'Hare Thomas; Corbin Amie S; Druker Brian J
Targeted CML therapy: controlling drug resistance, seeking cure.
Current opinion in genetics & development 2006;16(1):92-9.
2006: Schittenhelm Marcus M; Shiraga Sharon; Schroeder Arin; Corbin Amie S; Griffith Diana; Lee Francis Y; Bokemeyer Carsten; Deininger Michael W N; Druker Brian J; Heinrich Michael C
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Cancer research 2006;66(1):473-81.
2005: Chuah C; Barnes D J; Kwok M; Corbin A; Deininger M W N; Druker B J; Melo J V
Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cells.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(11):1896-904.
2005: Crossman L C; O'Hare T; Lange T; Willis S G; Stoffregen E P; Corbin A S; O'Brien S G; Heinrich M C; Druker B J; Middleton P G; Deininger M W N
A single nucleotide polymorphism in the coding region of ABL and its effects on sensitivity to imatinib.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(11):1859-62.
2005: Levine Ross L; Loriaux Marc; Huntly Brian J P; Loh Mignon L; Beran Miroslav; Stoffregen Eric; Berger Roland; Clark Jennifer J; Willis Stephanie G; Nguyen Kim T; Flores Nikki J; Estey Elihu; Gattermann Norbert; Armstrong Scott; Look A Thomas; Griffin James D; Bernard Olivier A; Heinrich Michael C; Gilliland D Gary; Druker Brian; Deininger Michael W N
The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.
Blood 2005;106(10):3377-9.
2005: Aichberger Karl J; Mayerhofer Matthias; Krauth Maria-Theresa; Vales Anja; Kondo Rudin; Derdak Sophia; Pickl Winfried F; Selzer Edgar; Deininger Michael; Druker Brian J; Sillaber Christian; Esterbauer Harald; Valent Peter
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Cancer research 2005;65(20):9436-44.
2005: O'Hare Thomas; Druker Brian J
BIRB-796 is not an effective ABL(T315I) inhibitor.
Nature biotechnology 2005;23(10):1209-10; author reply 1210-1.
2005: O'Hare Thomas; Walters Denise K; Stoffregen Eric P; Sherbenou Daniel W; Heinrich Michael C; Deininger Michael W N; Druker Brian J
Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6987-93.
2005: Willis Stephanie G; Lange Thoralf; Demehri Shadmehr; Otto Sandra; Crossman Lucy; Niederwieser Dietger; Stoffregen Eric P; McWeeney Shannon; Kovacs Ines; Park Byung; Druker Brian J; Deininger Michael W
High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy.
Blood 2005;106(6):2128-37.
2005: Crossman Lucy C; Druker Brian J; Deininger Michael W N; Pirmohamed Munir; Wang Lihui; Clark Richard E
hOCT 1 and resistance to imatinib.
Blood 2005;106(3):1133-4; author reply 1134.
2005: Aebersold Ruedi; Anderson Leigh; Caprioli Richard; Druker Brian; Hartwell Leland; Smith Richard
Perspective: a program to improve protein biomarker discovery for cancer.
Journal of proteome research 2005;4(4):1104-9.
2005: Corbin Amie S; Demehri Shadmehr; Griswold Ian J; Wang Yihan; Metcalf Chester A; Sundaramoorthi Raji; Shakespeare William C; Snodgrass Joseph; Wardwell Scott; Dalgarno David; Iuliucci John; Sawyer Tomi K; Heinrich Michael C; Druker Brian J; Deininger Michael W N
In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.
Blood 2005;106(1):227-34.
2005: O'Hare Thomas; Walters Denise K; Stoffregen Eric P; Jia Taiping; Manley Paul W; Mestan Jürgen; Cowan-Jacob Sandra W; Lee Francis Y; Heinrich Michael C; Deininger Michael W N; Druker Brian J
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.
Cancer research 2005;65(11):4500-5.
2005: Mayerhofer Matthias; Aichberger Karl J; Florian Stefan; Krauth Maria-Theresa; Hauswirth Alexander W; Derdak Sophia; Sperr Wolfgang R; Esterbauer Harald; Wagner Oswald; Marosi Christine; Pickl Winfried F; Deininger Michael; Weisberg Ellen; Druker Brian J; Griffin James D; Sillaber Christian; Valent Peter
Identification of mTOR as a novel bifunctional target in chronic myeloid leukemia: dissection of growth-inhibitory and VEGF-suppressive effects of rapamycin in leukemic cells.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(8):960-2.
2005: Tseng Ping-Hui; Lin Ho-Pi; Zhu Jiuxiang; Chen Kuen-Feng; Hade Erinn M; Young Donn C; Byrd John C; Grever Michael; Johnson Kara; Druker Brian J; Chen Ching-Shih
Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance.
Blood 2005;105(10):4021-7.
2005: Crossman Lucy C; Mori Motomi; Hsieh Yi-Ching; Lange Thoralf; Paschka Peter; Harrington Christina A; Krohn Knut; Niederwieser Dietger W; Hehlmann Rüdiger; Hochhaus Andreas; Druker Brian J; Deininger Michael W N
In chronic myeloid leukemia white cells from cytogenetic responders and non-responders to imatinib have very similar gene expression signatures.
Haematologica 2005;90(4):459-64.
2005: Demehri S; Paschka P; Schultheis B; Lange T; Koizumi T; Sugimoto T; Branford S; Lim L C; Kegel T; Martinelli G; Hochhaus A; Druker B J; Deininger M W N
e8a2 BCR-ABL: more frequent than other atypical BCR-ABL variants?
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2005;19(4):681-4.
2005: Deininger Michael; Buchdunger Elisabeth; Druker Brian J
The development of imatinib as a therapeutic agent for chronic myeloid leukemia.
Blood 2005;105(7):2640-53.
2005: Walters Denise K; Stoffregen Eric P; Heinrich Michael C; Deininger Michael W; Druker Brian J
RNAi-induced down-regulation of FLT3 expression in AML cell lines increases sensitivity to MLN518.
Blood 2005;105(7):2952-4.
2005: O'Hare Thomas; Walters Denise K; Deininger Michael W N; Druker Brian J
AMN107: tightening the grip of imatinib.
Cancer cell 2005;7(2):117-9.
2004: Corbin Amie S; Griswold Ian J; La Rosée Paul; Yee Kevin W H; Heinrich Michael C; Reimer Corinne L; Druker Brian J; Deininger Michael W N
Sensitivity of oncogenic KIT mutants to the kinase inhibitors MLN518 and PD180970.
Blood 2004;104(12):3754-7.
2004: Grossmann A H; Kolibaba K S; Willis S G; Corbin A S; Langdon W S; Deininger M W N; Druker B J
Catalytic domains of tyrosine kinases determine the phosphorylation sites within c-Cbl.
FEBS letters 2004;577(3):555-62.
2004: Griswold Ian J; Shen Lei J; La Rosée Paul; Demehri Shadmehr; Heinrich Michael C; Braziel Rita M; McGreevey Laura; Haley Andrea D; Giese Neill; Druker Brian J; Deininger Michael W N
Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis.
Blood 2004;104(9):2912-8.
2004: O'Hare Thomas; Pollock Roy; Stoffregen Eric P; Keats Jeffrey A; Abdullah Omar M; Moseson Erika M; Rivera Victor M; Tang Hao; Metcalf Chester A; Bohacek Regine S; Wang Yihan; Sundaramoorthi Raji; Shakespeare William C; Dalgarno David; Clackson Tim; Sawyer Tomi K; Deininger Michael W; Druker Brian J
Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
Blood 2004;104(8):2532-9.
2004: Leis Jose F; Primack Steven L; Schubach Susan E; Curtin Peter T; Druker Brian J; Maziarz Richard T
Management of life-threatening pulmonary leukostasis with single agent imatinib mesylate during CML myeloid blast crisis.
Haematologica 2004;89(9):ECR30.
2004: Deininger Michael W N; Druker Brian J
SRCircumventing imatinib resistance.
Cancer cell 2004;6(2):108-10.
2004: Druker Brian J
Imatinib: paradigm or anomaly?
Cell cycle (Georgetown, Tex.) 2004;3(7):833-5.
2004: Lim Yoon-Pin; Wong Chow Yin; Ooi London Lucien; Druker Brian J; Epstein Richard J
Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):3980-7.
2004: Mauro Michael J; Druker Brian J; Maziarz Richard T
Divergent clinical outcome in two CML patients who discontinued imatinib therapy after achieving a molecular remission.
Leukemia research 2004;28 Suppl 1():S71-3.
2004: Lydon Nicholas B; Druker Brian J
Lessons learned from the development of imatinib.
Leukemia research 2004;28 Suppl 1():S29-38.
2004: Leis Jose F; Stepan Daniel E; Curtin Peter T; Ford John M; Peng Bin; Schubach Susan; Druker Brian J; Maziarz Richard T
Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571).
Leukemia & lymphoma 2004;45(4):695-8.
2004: Deininger M W N; McGreevey L; Willis S; Bainbridge T M; Druker B J; Heinrich M C
Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2004;18(4):864-71.
2004: Peng Bin; Hayes Michael; Resta Debra; Racine-Poon Amy; Druker Brian J; Talpaz Moshe; Sawyers Charles L; Rosamilia Marianne; Ford John; Lloyd Peter; Capdeville Renaud
Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):935-42.
2004: Gaston Isabelle; Johnson Kara J; Oda Tsukasa; Bhat Arun; Reis Margaret; Langdon Wallace; Shen Lei; Deininger Michael W; Druker Brian J
Coexistence of phosphotyrosine-dependent and -independent interactions between Cbl and Bcr-Abl.
Experimental hematology 2004;32(1):113-21.
2004: O'Dwyer Michael E; Mauro Michael J; Blasdel Carolyn; Farnsworth Melanie; Kurilik Gwen; Hsieh Yi-Ching; Mori Motomi; Druker Brian J
Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate.
Blood 2004;103(2):451-5.
2004: La Rosée Paul; Johnson Kara; Corbin Amie S; Stoffregen Eric P; Moseson Erika M; Willis Stephanie; Mauro Michael M; Melo Junia V; Deininger Michael W; Druker Brian J
In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines.
Blood 2004;103(1):208-15.
2004: Druker Brian J
Imatinib as a paradigm of targeted therapies.
Advances in cancer research 2004;91():1-30.
2004: Druker Brian J
Molecularly targeted therapy: have the floodgates opened?
The oncologist 2004;9(4):357-60.
2004: Al-Ali Haifa-Kathrin; Heinrich Michael Charles; Lange Thoralf; Krahl Rainer; Mueller Matthias; Müller Christel; Niederwieser Dietger; Druker Brian James; Deininger Michael Werner Nikolaus
High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.
The hematology journal : the official journal of the European Haematology Association / EHA 2004;5(1):55-60.
2003: Lim Yoon-Pin; Diong Lang-Shi; Qi Robert; Druker Brian J; Epstein Richard J
Phosphoproteomic fingerprinting of epidermal growth factor signaling and anticancer drug action in human tumor cells.
Molecular cancer therapeutics 2003;2(12):1369-77.
2003: Dinulescu Daniela M; Wood Lisa J; Shen Lei; Loriaux Marc; Corless Christopher L; Gross Alec W; Ren Ruibao; Deininger Michael W N; Druker Brian J
c-CBL is not required for leukemia induction by Bcr-Abl in mice.
Oncogene 2003;22(55):8852-60.
2003: Heinrich Michael C; Corless Christopher L; Demetri George D; Blanke Charles D; von Mehren Margaret; Joensuu Heikki; McGreevey Laura S; Chen Chang-Jie; Van den Abbeele Annick D; Druker Brian J; Kiese Beate; Eisenberg Burton; Roberts Peter J; Singer Samuel; Fletcher Christopher D M; Silberman Sandra; Dimitrijevic Sasa; Fletcher Jonathan A
Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4342-9.
2003: Druker Brian J
David A. Karnofsky Award lecture. Imatinib as a paradigm of targeted therapies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23 Suppl):239s-245s.
2003: Miura-Shimura Yuko; Duan Lei; Rao Navin L; Reddi Alagarsamy L; Shimura Hideki; Rottapel Rob; Druker Brain J; Tsygankov Alexander; Band Vimla; Band Hamid
Cbl-mediated ubiquitinylation and negative regulation of Vav.
The Journal of biological chemistry 2003;278(40):38495-504.
2003: Deininger Michael W N; Druker Brian J
Specific targeted therapy of chronic myelogenous leukemia with imatinib.
Pharmacological reviews 2003;55(3):401-23.
2003: Fraunfelder Frederick W; Solomon Jonathan; Druker Brian J; Esmaeli Bita; Kuyl Jennifer
Ocular side-effects associated with imatinib mesylate (Gleevec).
Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 2003;19(4):371-5.
2003: O'Dwyer Michael E; Mauro Michael J; Druker Brian J
STI571 as a targeted therapy for CML.
Cancer investigation 2003;21(3):429-38.
2003: Frater John L; Tallman Martin S; Variakojis Daina; Druker Brian J; Resta Debra; Riley Mary Beth; Hrisinko Mary Ann; Peterson LoAnn C
Chronic myeloid leukemia following therapy with imatinib mesylate (Gleevec). Bone marrow histopathology and correlation with genetic status.
American journal of clinical pathology 2003;119(6):833-41.
2003: Druker Brian J
Imatinib mesylate in the treatment of chronic myeloid leukaemia.
Expert opinion on pharmacotherapy 2003;4(6):963-71.
2003: Hahn Elizabeth A; Glendenning G Alastair; Sorensen Mark V; Hudgens Stacie A; Druker Brian J; Guilhot Francois; Larson Richard A; O'Brien Stephen G; Dobrez Deborah G; Hensley Martee L; Cella David;
Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(11):2138-46.
2003: Corbin Amie S; La Rosée Paul; Stoffregen Eric P; Druker Brian J; Deininger Michael W
Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib.
Blood 2003;101(11):4611-4.
2003: Kurzrock Razelle; Kantarjian Hagop M; Druker Brian J; Talpaz Moshe
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics.
Annals of internal medicine 2003;138(10):819-30.
2003: Druker Brian J
Chronic myeloid leukemia in the imatinib era.
Seminars in hematology 2003;40(2 Suppl 2):1-3.
2003: Deininger Michael W N; O'Brien Stephen G; Ford John M; Druker Brian J
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(8):1637-47.
2003: Druker Brian J
Overcoming resistance to imatinib by combining targeted agents.
Molecular cancer therapeutics 2003;2(3):225-6.
2003: O'Dwyer M E; Gatter K M; Loriaux M; Druker B J; Olson S B; Magenis R E; Lawce H; Mauro M J; Maziarz R T; Braziel R M
Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylate.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2003;17(3):481-7.
2003: O'Brien Stephen G; Guilhot François; Larson Richard A; Gathmann Insa; Baccarani Michele; Cervantes Francisco; Cornelissen Jan J; Fischer Thomas; Hochhaus Andreas; Hughes Timothy; Lechner Klaus; Nielsen Johan L; Rousselot Philippe; Reiffers Josy; Saglio Giuseppe; Shepherd John; Simonsson Bengt; Gratwohl Alois; Goldman John M; Kantarjian Hagop; Taylor Kerry; Verhoef Gregor; Bolton Ann E; Capdeville Renaud; Druker Brian J;
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
The New England journal of medicine 2003;348(11):994-1004.
2003: Druker Brian J
Imatinib alone and in combination for chronic myeloid leukemia.
Seminars in hematology 2003;40(1):50-8.
2003: La Rosée Paul; Shen Lei; Stoffregen Eric P; Deininger Michael; Druker Brian J
No correlation between the proliferative status of Bcr-Abl positive cell lines and the proapoptotic activity of imatinib mesylate (Gleevec/Glivec).
The hematology journal : the official journal of the European Haematology Association / EHA 2003;4(6):413-9.
2002: Moses Ashlee V; Jarvis Michael A; Raggo Camilo; Bell Yolanda C; Ruhl Rebecca; Luukkonen B G Mattias; Griffith Diana J; Wait Cecily L; Druker Brian J; Heinrich Michael C; Nelson Jay A; Fruh Klaus
A functional genomics approach to Kaposi's sarcoma.
Annals of the New York Academy of Sciences 2002;975():180-91.
2002: La Rosée Paul; Corbin Amie S; Stoffregen Eric P; Deininger Michael W; Druker Brian J
Activity of the Bcr-Abl kinase inhibitor PD180970 against clinically relevant Bcr-Abl isoforms that cause resistance to imatinib mesylate (Gleevec, STI571).
Cancer research 2002;62(24):7149-53.
2002: Druker Brian J
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
Oncogene 2002;21(56):8541-6.
2002: Druker Brian J
Taking aim at Ewing's sarcoma: is KIT a target and will imatinib work?
Journal of the National Cancer Institute 2002;94(22):1660-1.
2002: Hochhaus A; Kreil S; Corbin A S; La Rosée P; Müller M C; Lahaye T; Hanfstein B; Schoch C; Cross N C P; Berger U; Gschaidmeier H; Druker B J; Hehlmann R
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(11):2190-6.
2002: Druker Brian J
Imatinib and chronic myeloid leukemia: validating the promise of molecularly targeted therapy.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 5():S70-6.
2002: Ottmann Oliver G; Druker Brian J; Sawyers Charles L; Goldman John M; Reiffers Jose; Silver Richard T; Tura Sante; Fischer Thomas; Deininger Michael W; Schiffer Charles A; Baccarani Michele; Gratwohl Alois; Hochhaus Andreas; Hoelzer Dieter; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; O'Brien Stephen G
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.
Blood 2002;100(6):1965-71.
2002: O'Dwyer Michael E; Mauro Michael J; Kurilik Gwen; Mori Motomi; Balleisen Suzanne; Olson Susan; Magenis Ellen; Capdeville Renaud; Druker Brian J
The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML.
Blood 2002;100(5):1628-33.
2002: Demetri George D; von Mehren Margaret; Blanke Charles D; Van den Abbeele Annick D; Eisenberg Burton; Roberts Peter J; Heinrich Michael C; Tuveson David A; Singer Samuel; Janicek Milos; Fletcher Jonathan A; Silverman Stuart G; Silberman Sandra L; Capdeville Renaud; Kiese Beate; Peng Bin; Dimitrijevic Sasa; Druker Brian J; Corless Christopher; Fletcher Christopher D M; Joensuu Heikki
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
The New England journal of medicine 2002;347(7):472-80.
2002: Moses Ashlee V; Jarvis Michael A; Raggo Camilo; Bell Yolanda C; Ruhl Rebecca; Luukkonen B G Mattias; Griffith Diana J; Wait Cecily L; Druker Brian J; Heinrich Michael C; Nelson Jay A; Früh Klaus
Kaposi's sarcoma-associated herpesvirus-induced upregulation of the c-kit proto-oncogene, as identified by gene expression profiling, is essential for the transformation of endothelial cells.
Journal of virology 2002;76(16):8383-99.
2002: Corbin Amie S; Buchdunger Elisabeth; Pascal Furet; Druker Brian J
Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.
The Journal of biological chemistry 2002;277(35):32214-9.
2002: La Rosée Paul; Johnson Kara; O'Dwyer Michael E; Druker Brian J
In vitro studies of the combination of imatinib mesylate (Gleevec) and arsenic trioxide (Trisenox) in chronic myelogenous leukemia.
Experimental hematology 2002;30(7):729-37.
2002: La Rosée P; O'Dwyer M E; Druker B J
Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2002;16(7):1213-9.
2002: Braziel Rita M; Launder Teresa M; Druker Brian J; Olson Susan B; Magenis R Ellen; Mauro Michael J; Sawyers Charles L; Paquette Ronald L; O'Dwyer Michael E
Hematopathologic and cytogenetic findings in imatinib mesylate-treated chronic myelogenous leukemia patients: 14 months' experience.
Blood 2002;100(2):435-41.
2002: Wertheim Jason A; Forsythe Kevin; Druker Brian J; Hammer Daniel; Boettiger David; Pear Warren S
BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
Blood 2002;99(11):4122-30.
2002: Dash Ajeeta B; Williams Ifor R; Kutok Jeffery L; Tomasson Michael H; Anastasiadou Ema; Lindahl Kathleen; Li Shaoguang; Van Etten Richard A; Borrow Julian; Housman David; Druker Brian; Gilliland D Gary
A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(11):7622-7.
2002: Sawyers Charles L; Hochhaus Andreas; Feldman Eric; Goldman John M; Miller Carole B; Ottmann Oliver G; Schiffer Charles A; Talpaz Moshe; Guilhot Francois; Deininger Michael W N; Fischer Thomas; O'Brien Steve G; Stone Richard M; Gambacorti-Passerini Carlo B; Russell Nigel H; Reiffers Jose J; Shea Thomas C; Chapuis Bernard; Coutre Steven; Tura Sante; Morra Enrica; Larson Richard A; Saven Alan; Peschel Christian; Gratwohl Alois; Mandelli Franco; Ben-Am Monique; Gathmann Insa; Capdeville Renaud; Paquette Ronald L; Druker Brian J
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.
Blood 2002;99(10):3530-9.
2002: O'Dwyer Michael E; La Rosée Paul; Nimmanapalli Ramedivi; Bhalla Kapil N; Druker Brian J
Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide.
Seminars in hematology 2002;39(2 Suppl 1):18-21.
2002: Heinrich Michael C; Blanke Charles D; Druker Brian J; Corless Christopher L
Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1692-703.
2002: Talpaz Moshe; Silver Richard T; Druker Brian J; Goldman John M; Gambacorti-Passerini Carlo; Guilhot Francois; Schiffer Charles A; Fischer Thomas; Deininger Michael W N; Lennard Anne L; Hochhaus Andreas; Ottmann Oliver G; Gratwohl Alois; Baccarani Michele; Stone Richard; Tura Sante; Mahon Francois-Xavier; Fernandes-Reese Sofia; Gathmann Insa; Capdeville Renaud; Kantarjian Hagop M; Sawyers Charles L
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.
Blood 2002;99(6):1928-37.
2002: Lekmine Fatima; Sassano Antonella; Uddin Shahab; Majchrzak Beata; Miura Osamu; Druker Brian J; Fish Eleanor N; Imamoto Akira; Platanias Leonidas C
The CrkL adapter protein is required for type I interferon-dependent gene transcription and activation of the small G-protein Rap1.
Biochemical and biophysical research communications 2002;291(4):744-50.
2002: Druker Brian J
Perspectives on the development of a molecularly targeted agent.
Cancer cell 2002;1(1):31-6.
2002: Kantarjian Hagop; Sawyers Charles; Hochhaus Andreas; Guilhot Francois; Schiffer Charles; Gambacorti-Passerini Carlo; Niederwieser Dietger; Resta Debra; Capdeville Renaud; Zoellner Ulrike; Talpaz Moshe; Druker Brian; Goldman John; O'Brien Stephen G; Russell Nigel; Fischer Thomas; Ottmann Oliver; Cony-Makhoul Pascale; Facon Thierry; Stone Richard; Miller Carole; Tallman Martin; Brown Randy; Schuster Michael; Loughran Thomas; Gratwohl Alois; Mandelli Franco; Saglio Giuseppe; Lazzarino Mario; Russo Domenico; Baccarani Michele; Morra Enrica;
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
The New England journal of medicine 2002;346(9):645-52.
2002: Mauro Michael J; O'Dwyer Michael; Heinrich Michael C; Druker Brian J
STI571: a paradigm of new agents for cancer therapeutics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(1):325-34.
2002: Druker Brian J; O'Brien Stephen G; Cortes Jorge; Radich Jerald
Chronic myelogenous leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():111-35.
2002: Druker Brian J
STI571 (Gleevec) as a paradigm for cancer therapy.
Trends in molecular medicine 2002;8(4 Suppl):S14-8.
2002: O'Dwyer Michael E; Mauro Michael J; Druker Brian J
Recent advancements in the treatment of chronic myelogenous leukemia.
Annual review of medicine 2002;53():369-81.
2001: Druker B J
Investigator profile. Brian J. Druker, M.D. Interview by Vicki P. Glaser.
Journal of hematotherapy & stem cell research 2001;10(6):721-4.
2001: Druker B J
Chronic myeloid leukemia. Sceptical scientists.
Lancet 2001;358 Suppl():S11.
2001: Rao N; Ghosh A K; Ota S; Zhou P; Reddi A L; Hakezi K; Druker B K; Wu J; Band H
The non-receptor tyrosine kinase Syk is a target of Cbl-mediated ubiquitylation upon B-cell receptor stimulation.
The EMBO journal 2001;20(24):7085-95.
2001: Druker B J
ST1571: a paradigm for clinical trials of molecularly targeted agents.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 2001;55(9-10):529-30.
2001: Goldman J M; Druker B J
Chronic myeloid leukemia: current treatment options.
Blood 2001;98(7):2039-42.
2001: Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross N C; Linkesch W; Druker B J; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Roots of clinical resistance to STI-571 cancer therapy.
Science (New York, N.Y.) 2001;293(5538):2163.
2001: Mauro M J; O'Dwyer M E; Druker B J
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy.
Cancer chemotherapy and pharmacology 2001;48 Suppl 1():S77-8.
2001: Buchdunger E; Matter A; Druker B J
Bcr-Abl inhibition as a modality of CML therapeutics.
Biochimica et biophysica acta 2001;1551(1):M11-8.
2001: Druker B
Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia.
Seminars in hematology 2001;38(3 Suppl 8):9-14.
2001: Druker B J
Current treatment approaches for chronic myelogenous leukemia.
Cancer journal (Sudbury, Mass.) 2001;7 Suppl 1():S14-8.
2001: O'Dwyer M E; Druker B J
Chronic myelogenous leukaemia--new therapeutic principles.
Journal of internal medicine 2001;250(1):3-9.
2001: O'Dwyer M E; Druker B J
The role of the tyrosine kinase inhibitor STI571 in the treatment of cancer.
Current cancer drug targets 2001;1(1):49-57.
2001: Mauro M J; Druker B J
STI571: a gene product-targeted therapy for leukemia.
Current oncology reports 2001;3(3):223-7.
2001: Joensuu H; Roberts P J; Sarlomo-Rikala M; Andersson L C; Tervahartiala P; Tuveson D; Silberman S; Capdeville R; Dimitrijevic S; Druker B; Demetri G D
Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
The New England journal of medicine 2001;344(14):1052-6.
2001: Druker B J; Sawyers C L; Kantarjian H; Resta D J; Reese S F; Ford J M; Capdeville R; Talpaz M
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.
The New England journal of medicine 2001;344(14):1038-42.
2001: Druker B J; Talpaz M; Resta D J; Peng B; Buchdunger E; Ford J M; Lydon N B; Kantarjian H; Capdeville R; Ohno-Jones S; Sawyers C L
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
The New England journal of medicine 2001;344(14):1031-7.
2001: Guris D L; Fantes J; Tara D; Druker B J; Imamoto A
Mice lacking the homologue of the human 22q11.2 gene CRKL phenocopy neurocristopathies of DiGeorge syndrome.
Nature genetics 2001;27(3):293-8.
2001: Grumbach I M; Mayer I A; Uddin S; Lekmine F; Majchrzak B; Yamauchi H; Fujita S; Druker B; Fish E N; Platanias L C
Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
British journal of haematology 2001;112(2):327-36.
2001: Mauro M J; Druker B J
Chronic myelogenous leukemia.
Current opinion in oncology 2001;13(1):3-7.
2001: Druker B J; Sawyers C L; Capdeville R; Ford J M; Baccarani M; Goldman J M
Chronic myelogenous leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2001;():87-112.
2001: Mauro M J; Druker B J
STI571: targeting BCR-ABL as therapy for CML.
The oncologist 2001;6(3):233-8.
2000: O'Dwyer M E; Druker B J
STI571: an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myelogenous leukaemia.
The lancet oncology 2000;1():207-11.
2000: O'Dwyer M E; Druker B J
Status of bcr-abl tyrosine kinase inhibitors in chronic myelogenous leukemia.
Current opinion in oncology 2000;12(6):594-7.
2000: Thiesing J T; Ohno-Jones S; Kolibaba K S; Druker B J
Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.
Blood 2000;96(9):3195-9.
2000: Buchdunger E; Cioffi C L; Law N; Stover D; Ohno-Jones S; Druker B J; Lydon N B
Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
The Journal of pharmacology and experimental therapeutics 2000;295(1):139-45.
2000: Heinrich M C; Griffith D J; Druker B J; Wait C L; Ott K A; Zigler A J
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor.
Blood 2000;96(3):925-32.
2000: Alsayed Y; Modi S; Uddin S; Mahmud N; Druker B J; Fish E N; Hoffman R; Platanias L C
All-trans-retinoic acid induces tyrosine phosphorylation of the CrkL adapter in acute promyelocytic leukemia cells.
Experimental hematology 2000;28(7):826-32.
2000: Wilbanks A M; Mahajan S; Frank D A; Druker B J; Gilliland D G; Carroll M
TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.
Experimental hematology 2000;28(5):584-93.
2000: Rao N; Lupher M L; Ota S; Reedquist K A; Druker B J; Band H
The linker phosphorylation site Tyr292 mediates the negative regulatory effect of Cbl on ZAP-70 in T cells.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(9):4616-26.
2000: Gaston I; Stenberg P E; Bhat A; Druker B J
Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells.
Experimental hematology 2000;28(3):351.
2000: Rhodes J; York R D; Tara D; Tajinda K; Druker B J
CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells.
Experimental hematology 2000;28(3):305-10.
2000: Oda A; Ikeda Y; Ochs H D; Druker B J; Ozaki K; Handa M; Ariga T; Sakiyama Y; Witte O N; Wahl M I
Rapid tyrosine phosphorylation and activation of Bruton's tyrosine/Tec kinases in platelets induced by collagen binding or CD32 cross-linking.
Blood 2000;95(5):1663-70.
2000: Alsayed Y; Uddin S; Ahmad S; Majchrzak B; Druker B J; Fish E N; Platanias L C
IFN-gamma activates the C3G/Rap1 signaling pathway.
Journal of immunology (Baltimore, Md. : 1950) 2000;164(4):1800-6.
2000: Gaston I; Stenberg P E; Bhat A; Druker B J
Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells.
Experimental hematology 2000;28(1):77-86.
2000: Druker B J; Lydon N B
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
The Journal of clinical investigation 2000;105(1):3-7.
2000: Ota S; Hazeki K; Rao N; Lupher M L; Andoniou C E; Druker B; Band H
The RING finger domain of Cbl is essential for negative regulation of the Syk tyrosine kinase.
The Journal of biological chemistry 2000;275(1):414-22.
1999: Oda A; Miyakawa Y; Druker B J; Ozaki K; Ohashi H; Kato T; Miyazaki H; Handa M; Ikebuchi K; Ikeda Y
Thrombopoietin-induced signal transduction and potentiation of platelet activation.
Thrombosis and haemostasis 1999;82(2):377-84.
1999: Platanias L C; Uddin S; Bruno E; Korkmaz M; Ahmad S; Alsayed Y; Van Den Berg D; Druker B J; Wickrema A; Hoffman R
CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors.
Experimental hematology 1999;27(8):1315-21.
1999: Sawyers C L; Druker B
Tyrosine kinase inhibitors in chronic myeloid leukemia.
The cancer journal from Scientific American 1999;5(2):63-9.
1999: Kolibaba K S; Bhat A; Heaney C; Oda T; Druker B J
CRKL binding to BCR-ABL and BCR-ABL transformation.
Leukemia & lymphoma 1999;33(1-2):119-26.
1999: Tomasson M H; Williams I R; Hasserjian R; Udomsakdi C; McGrath S M; Schwaller J; Druker B; Gilliland D G
TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor.
Blood 1999;93(5):1707-14.
1999: Fish E N; Uddin S; Korkmaz M; Majchrzak B; Druker B J; Platanias L C
Activation of a CrkL-stat5 signaling complex by type I interferons.
The Journal of biological chemistry 1999;274(2):571-3.
1998: Lupher M L; Rao N; Lill N L; Andoniou C E; Miyake S; Clark E A; Druker B; Band H
Cbl-mediated negative regulation of the Syk tyrosine kinase. A critical role for Cbl phosphotyrosine-binding domain binding to Syk phosphotyrosine 323.
The Journal of biological chemistry 1998;273(52):35273-81.
1998: Ozaki K; Oda A; Wakao H; Rhodes J; Druker B J; Ishida A; Wakui M; Okamoto S; Morita K; Handa M; Komatsu N; Ohashi H; Miyajima A; Ikeda Y
Thrombopoietin induces association of Crkl with STAT5 but not STAT3 in human platelets.
Blood 1998;92(12):4652-62.
1998: Bhat A; Johnson K J; Oda T; Corbin A S; Druker B J
Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
The Journal of biological chemistry 1998;273(48):32360-8.
1998: Oda A; Ochs H D; Druker B J; Ozaki K; Watanabe C; Handa M; Miyakawa Y; Ikeda Y
Collagen induces tyrosine phosphorylation of Wiskott-Aldrich syndrome protein in human platelets.
Blood 1998;92(6):1852-8.
1998: Senechal K; Heaney C; Druker B; Sawyers C L
Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells.
Molecular and cellular biology 1998;18(9):5082-90.
1998: Oda A; Sawada K; Druker B J; Ozaki K; Takano H; Koizumi K; Fukada Y; Handa M; Koike T; Ikeda Y
Erythropoietin induces tyrosine phosphorylation of Jak2, STAT5A, and STAT5B in primary cultured human erythroid precursors.
Blood 1998;92(2):443-51.
1998: Miyake S; Lupher M L; Druker B; Band H
The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(14):7927-32.
1998: Oliveira M L; Roberts T M; Druker B J; Armelin M C
Mapping of polyomavirus middle T domain that is responsible for AP-1 activation.
Oncogene 1998;16(23):2975-82.
1997: Astier A; Manié S N; Law S F; Canty T; Haghayghi N; Druker B J; Salgia R; Golemis E A; Freedman A S
Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells.
Leukemia & lymphoma 1997;28(1-2):65-72.
1997: Kolibaba K S; Druker B J
Protein tyrosine kinases and cancer.
Biochimica et biophysica acta 1997;1333(3):F217-48.
1997: Hallek M; Neumann C; Schäffer M; Danhauser-Riedl S; von Bubnoff N; de Vos G; Druker B J; Yasukawa K; Griffin J D; Emmerich B
Signal transduction of interleukin-6 involves tyrosine phosphorylation of multiple cytosolic proteins and activation of Src-family kinases Fyn, Hck, and Lyn in multiple myeloma cell lines.
Experimental hematology 1997;25(13):1367-77.
1997: Carroll M; Ohno-Jones S; Tamura S; Buchdunger E; Zimmermann J; Lydon N B; Gilliland D G; Druker B J
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
Blood 1997;90(12):4947-52.
1997: Pestina T I; Stenberg P E; Druker B J; Steward S A; Hutson N K; Barrie R J; Jackson C W
Identification of the Src family kinases, Lck and Fgr in platelets. Their tyrosine phosphorylation status and subcellular distribution compared with other Src family members.
Arteriosclerosis, thrombosis, and vascular biology 1997;17(11):3278-85.
1997: Ahmad S; Alsayed Y M; Druker B J; Platanias L C
The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein.
The Journal of biological chemistry 1997;272(48):29991-4.
1997: Oda T; Kujovich J; Reis M; Newman B; Druker B J
Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
Oncogene 1997;15(11):1255-62.
1997: Astier A; Manié S N; Avraham H; Hirai H; Law S F; Zhang Y; Golemis E A; Fu Y; Druker B J; Haghayeghi N; Freedman A S; Avraham S
The related adhesion focal tyrosine kinase differentially phosphorylates p130Cas and the Cas-like protein, p105HEF1.
The Journal of biological chemistry 1997;272(32):19719-24.
1997: Bhat A; Kolibaba K; Oda T; Ohno-Jones S; Heaney C; Druker B J
Interactions of CBL with BCR-ABL and CRKL in BCR-ABL-transformed myeloid cells.
The Journal of biological chemistry 1997;272(26):16170-5.
1997: Manié S N; Astier A; Haghayeghi N; Canty T; Druker B J; Hirai H; Freedman A S
Regulation of integrin-mediated p130(Cas) tyrosine phosphorylation in human B cells. A role for p59(Fyn) and SHP2.
The Journal of biological chemistry 1997;272(25):15636-41.
1997: Barber D L; Mason J M; Fukazawa T; Reedquist K A; Druker B J; Band H; D'Andrea A D
Erythropoietin and interleukin-3 activate tyrosine phosphorylation of CBL and association with CRK adaptor proteins.
Blood 1997;89(9):3166-74.
1997: Miyakawa Y; Oda A; Druker B J; Ozaki K; Handa M; Ohashi H; Ikeda Y
Thrombopoietin and thrombin induce tyrosine phosphorylation of Vav in human blood platelets.
Blood 1997;89(8):2789-98.
1997: Ganju R K; Hatch W C; Avraham H; Ona M A; Druker B; Avraham S; Groopman J E
RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes.
The Journal of experimental medicine 1997;185(6):1055-63.
1997: Manié S N; Beck A R; Astier A; Law S F; Canty T; Hirai H; Druker B J; Avraham H; Haghayeghi N; Sattler M; Salgia R; Griffin J D; Golemis E A; Freedman A S
Involvement of p130(Cas) and p105(HEF1), a novel Cas-like docking protein, in a cytoskeleton-dependent signaling pathway initiated by ligation of integrin or antigen receptor on human B cells.
The Journal of biological chemistry 1997;272(7):4230-6.
1997: Avalos B R; Parker J M; Ware D A; Hunter M G; Sibert K A; Druker B J
Dissociation of the Jak kinase pathway from G-CSF receptor signaling in neutrophils.
Experimental hematology 1997;25(2):160-8.
1997: Manié S N; Sattler M; Astier A; Phifer J S; Canty T; Morimoto C; Druker B J; Salgia R; Griffin J D; Freedman A S
Tyrosine phosphorylation of the product of the c-cbl protooncogene is [corrected] induced after integrin stimulation.
Experimental hematology 1997;25(1):45-50.
1997: Heaney C; Kolibaba K; Bhat A; Oda T; Ohno S; Fanning S; Druker B J
Direct binding of CRKL to BCR-ABL is not required for BCR-ABL transformation.
Blood 1997;89(1):297-306.
1996: Oda A; Miyakawa Y; Druker B J; Ishida A; Ozaki K; Ohashi H; Wakui M; Handa M; Watanabe K; Okamoto S; Ikeda Y
Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.
Blood 1996;88(11):4304-13.
1996: Jain S K; Susa M; Keeler M L; Carlesso N; Druker B; Varticovski L
PI 3-kinase activation in BCR/abl-transformed hematopoietic cells does not require interaction of p85 SH2 domains with p210 BCR/abl.
Blood 1996;88(5):1542-50.
1996: Danhauser-Riedl S; Warmuth M; Druker B J; Emmerich B; Hallek M
Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.
Cancer research 1996;56(15):3589-96.
1996: Oda A; Ozaki K; Druker B J; Miyakawa Y; Miyazaki H; Handa M; Morita H; Ohashi H; Ikeda Y
p120c-cbl is present in human blood platelets and is differentially involved in signaling by thrombopoietin and thrombin.
Blood 1996;88(4):1330-8.
1996: Ottensmeier C; Swanson L; Strobel T; Druker B; Niloff J; Cannistra S A
Absence of constitutive EGF receptor activation in ovarian cancer cell lines.
British journal of cancer 1996;74(3):446-52.
1996: Hallek M; Danhauser-Riedl S; Herbst R; Warmuth M; Winkler A; Kolb H J; Druker B; Griffin J D; Emmerich B; Ullrich A
Interaction of the receptor tyrosine kinase p145c-kit with the p210bcr/abl kinase in myeloid cells.
British journal of haematology 1996;94(1):5-16.
1996: Egerton M; Moritz R L; Druker B; Kelso A; Simpson R J
Identification of the 70kD heat shock cognate protein (Hsc70) and alpha-actinin-1 as novel phosphotyrosine-containing proteins in T lymphocytes.
Biochemical and biophysical research communications 1996;224(3):666-74.
1996: Royal I; Raptis L; Druker B J; Marceau N
Down-regulation of cytokeratin 14 gene expression by the polyoma virus middle T antigen is dependent on c-Src association but independent of full transformation in rat liver nonparenchymal epithelial cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(6):737-43.
1996: Oda A; Miyakawa Y; Druker B J; Ozaki K; Yabusaki K; Shirasawa Y; Handa M; Kato T; Miyazaki H; Shimosaka A; Ikeda Y
Thrombopoietin primes human platelet aggregation induced by shear stress and by multiple agonists.
Blood 1996;87(11):4664-70.
1996: Neumann M; Wilisch A; Ma B C; Druker B J; Serfling E; Franza B R
BCR/ABL modulates the cytokine and retinoic acid response of c-Rel in human myeloid cells.
Anticancer research 1996;16(3A):1075-83.
1996: Druker B J; Tamura S; Buchdunger E; Ohno S; Segal G M; Fanning S; Zimmermann J; Lydon N B
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells.
Nature medicine 1996;2(5):561-6.
1996: Reedquist K A; Fukazawa T; Panchamoorthy G; Langdon W Y; Shoelson S E; Druker B J; Band H
Stimulation through the T cell receptor induces Cbl association with Crk proteins and the guanine nucleotide exchange protein C3G.
The Journal of biological chemistry 1996;271(14):8435-42.
1996: Panchamoorthy G; Fukazawa T; Miyake S; Soltoff S; Reedquist K; Druker B; Shoelson S; Cantley L; Band H
p120cbl is a major substrate of tyrosine phosphorylation upon B cell antigen receptor stimulation and interacts in vivo with Fyn and Syk tyrosine kinases, Grb2 and Shc adaptors, and the p85 subunit of phosphatidylinositol 3-kinase.
The Journal of biological chemistry 1996;271(6):3187-94.
1996: Miyakawa Y; Oda A; Druker B J; Miyazaki H; Handa M; Ohashi H; Ikeda Y
Thrombopoietin induces tyrosine phosphorylation of Stat3 and Stat5 in human blood platelets.
Blood 1996;87(2):439-46.
1996: Buchdunger E; Zimmermann J; Mett H; Meyer T; Müller M; Druker B J; Lydon N B
Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.
Cancer research 1996;56(1):100-4.
1995: Salgia R; Uemura N; Okuda K; Li J L; Pisick E; Sattler M; de Jong R; Druker B; Heisterkamp N; Chen L B
CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells.
The Journal of biological chemistry 1995;270(49):29145-50.
1995: Pignata C; Prasad K V; Hallek M; Druker B; Rudd C E; Robertson M J; Ritz J
Phosphorylation of src family lck tyrosine kinase following interleukin-12 activation of human natural killer cells.
Cellular immunology 1995;165(2):211-6.
1995: Wendtner C M; Schmitt B; Gruss H J; Druker B J; Emmerich B; Goodwin R G; Hallek M
CD30 ligand signal transduction involves activation of a tyrosine kinase and of mitogen-activated protein kinase in a Hodgkin's lymphoma cell line.
Cancer research 1995;55(18):4157-61.
1995: Fukazawa T; Reedquist K A; Trub T; Soltoff S; Panchamoorthy G; Druker B; Cantley L; Shoelson S E; Band H
The SH3 domain-binding T cell tyrosyl phosphoprotein p120. Demonstration of its identity with the c-cbl protooncogene product and in vivo complexes with Fyn, Grb2, and phosphatidylinositol 3-kinase.
The Journal of biological chemistry 1995;270(32):19141-50.
1995: Fukazawa T; Reedquist K A; Panchamoorthy G; Soltoff S; Trub T; Druker B; Cantley L; Shoelson S E; Band H
T cell activation-dependent association between the p85 subunit of the phosphatidylinositol 3-kinase and Grb2/phospholipase C-gamma 1-binding phosphotyrosyl protein pp36/38.
The Journal of biological chemistry 1995;270(34):20177-82.
1995: Miyakawa Y; Oda A; Druker B J; Kato T; Miyazaki H; Handa M; Ikeda Y
Recombinant thrombopoietin induces rapid protein tyrosine phosphorylation of Janus kinase 2 and Shc in human blood platelets.
Blood 1995;86(1):23-7.
1995: Oda A; Druker B J; Ariyoshi H; Smith M; Salzman E W
TMB-8 and dibucaine induce tyrosine phosphorylation and dephosphorylation of a common set of proteins in platelets.
The American journal of physiology 1995;269(1 Pt 1):C118-25.
1995: Avalos B R; Hunter M G; Parker J M; Ceselski S K; Druker B J; Corey S J; Mehta V B
Point mutations in the conserved box 1 region inactivate the human granulocyte colony-stimulating factor receptor for growth signal transduction and tyrosine phosphorylation of p75c-rel.
Blood 1995;85(11):3117-26.
1995: Oda T; Tamura S; Matsuguchi T; Griffin J D; Druker B J
The SH2 domain of ABL is not required for factor-independent growth induced by BCR-ABL in a murine myeloid cell line.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1995;9(2):295-301.
1995: Matsuguchi T; Inhorn R C; Carlesso N; Xu G; Druker B; Griffin J D
Tyrosine phosphorylation of p95Vav in myeloid cells is regulated by GM-CSF, IL-3 and steel factor and is constitutively increased by p210BCR/ABL.
The EMBO journal 1995;14(2):257-65.
1994: Okuda K; Matulonis U; Salgia R; Kanakura Y; Druker B; Griffin J D
Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1.
Experimental hematology 1994;22(11):1111-7.
1994: Oda T; Heaney C; Hagopian J R; Okuda K; Griffin J D; Druker B J
Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
The Journal of biological chemistry 1994;269(37):22925-8.
1994: Avalos B R; Broudy V C; Ceselski S K; Druker B J; Griffin J D; Hammond W P
Abnormal response to granulocyte colony-stimulating factor (G-CSF) in canine cyclic hematopoiesis is not caused by altered G-CSF receptor expression.
Blood 1994;84(3):789-94.
1994: Ramos-Morales F; Druker B J; Fischer S
Vav binds to several SH2/SH3 containing proteins in activated lymphocytes.
Oncogene 1994;9(7):1917-23.
1994: Campbell K S; Ogris E; Burke B; Su W; Auger K R; Druker B J; Schaffhausen B S; Roberts T M; Pallas D C
Polyoma middle tumor antigen interacts with SHC protein via the NPTY (Asn-Pro-Thr-Tyr) motif in middle tumor antigen.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(14):6344-8.
1994: Reedquist K A; Fukazawa T; Druker B; Panchamoorthy G; Shoelson S E; Band H
Rapid T-cell receptor-mediated tyrosine phosphorylation of p120, an Fyn/Lck Src homology 3 domain-binding protein.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(10):4135-9.
1994: Druker B J; Neumann M; Okuda K; Franza B R; Griffin J D
rel Is rapidly tyrosine-phosphorylated following granulocyte-colony stimulating factor treatment of human neutrophils.
The Journal of biological chemistry 1994;269(7):5387-90.
1994: Matsuguchi T; Salgia R; Hallek M; Eder M; Druker B; Ernst T J; Griffin J D
Shc phosphorylation in myeloid cells is regulated by granulocyte macrophage colony-stimulating factor, interleukin-3, and steel factor and is constitutively increased by p210BCR/ABL.
The Journal of biological chemistry 1994;269(7):5016-21.
1994: Carlesso N; Griffin J D; Druker B J
Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Oncogene 1994;9(1):149-56.
1994: Ley S C; Verbi W; Pappin D J; Druker B; Davies A A; Crumpton M J
Tyrosine phosphorylation of alpha tubulin in human T lymphocytes.
European journal of immunology 1994;24(1):99-106.
1993: Weiss M; Yokoyama C; Shikama Y; Naugle C; Druker B; Sieff C A
Human granulocyte-macrophage colony-stimulating factor receptor signal transduction requires the proximal cytoplasmic domains of the alpha and beta subunits.
Blood 1993;82(11):3298-306.
1993: Matulonis U; Salgia R; Okuda K; Druker B; Griffin J D
Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line.
Experimental hematology 1993;21(11):1460-6.
1993: Mayeux P; Dusanter-Fourt I; Muller O; Mauduit P; Sabbah M; Druker B; Vainchenker W; Fischer S; Lacombe C; Gisselbrecht S
Erythropoietin induces the association of phosphatidylinositol 3'-kinase with a tyrosine-phosphorylated protein complex containing the erythropoietin receptor.
European journal of biochemistry / FEBS 1993;216(3):821-8.
1993: Oda A; Druker B J; Ariyoshi H; Smith M; Salzman E W
pp60src is an endogenous substrate for calpain in human blood platelets.
The Journal of biological chemistry 1993;268(17):12603-8.
1992: Showers M O; Moreau J F; Linnekin D; Druker B; D'Andrea A D
Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation.
Blood 1992;80(12):3070-8.
1992: Epstein R J; Druker B J; Roberts T M; Stiles C D
Synthetic phosphopeptide immunogens yield activation-specific antibodies to the c-erbB-2 receptor.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(21):10435-9.
1992: Oda A; Druker B J; Smith M; Salzman E W
Association of pp60src with Triton X-100-insoluble residue in human blood platelets requires platelet aggregation and actin polymerization.
The Journal of biological chemistry 1992;267(28):20075-81.
1992: Egerton M; Ashe O R; Chen D; Druker B J; Burgess W H; Samelson L E
VCP, the mammalian homolog of cdc48, is tyrosine phosphorylated in response to T cell antigen receptor activation.
The EMBO journal 1992;11(10):3533-40.
1992: Hallek M; Druker B; Lepisto E M; Wood K W; Ernst T J; Griffin J D
Granulocyte-macrophage colony-stimulating factor and steel factor induce phosphorylation of both unique and overlapping signal transduction intermediates in a human factor-dependent hematopoietic cell line.
Journal of cellular physiology 1992;153(1):176-86.
1992: Druker B J; Sibert L; Roberts T M
Polyomavirus middle T-antigen NPTY mutants.
Journal of virology 1992;66(10):5770-6.
1992: Egerton M; Burgess W H; Chen D; Druker B J; Bretscher A; Samelson L E
Identification of ezrin as an 81-kDa tyrosine-phosphorylated protein in T cells.
Journal of immunology (Baltimore, Md. : 1950) 1992;149(6):1847-52.
1992: Bachelot C; Cano E; Grelac F; Saleun S; Druker B J; Levy-Toledano S; Fischer S; Rendu F
Functional implications of tyrosine protein phosphorylation in platelets. Simultaneous studies with different agonists and inhibitors.
The Biochemical journal 1992;284 ( Pt 3)():923-8.
1992: Okuda K; Sanghera J S; Pelech S L; Kanakura Y; Hallek M; Griffin J D; Druker B J
Granulocyte-macrophage colony-stimulating factor, interleukin-3, and steel factor induce rapid tyrosine phosphorylation of p42 and p44 MAP kinase.
Blood 1992;79(11):2880-7.
1992: Druker B; Okuda K; Matulonis U; Salgia R; Roberts T; Griffin J D
Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines.
Blood 1992;79(9):2215-20.
1992: Oda A; Druker B J; Smith M; Salzman E W
Inhibition by sodium nitroprusside or PGE1 of tyrosine phosphorylation induced in platelets by thrombin or ADP.
The American journal of physiology 1992;262(3 Pt 1):C701-7.
1992: Ling L E; Druker B J; Cantley L C; Roberts T M
Transformation-defective mutants of polyomavirus middle T antigen associate with phosphatidylinositol 3-kinase (PI 3-kinase) but are unable to maintain wild-type levels of PI 3-kinase products in intact cells.
Journal of virology 1992;66(3):1702-8.
1992: Epstein R J; Druker B J; Irminger J C; Jones S D; Roberts T M; Stiles C D
Extracellular calcium mimics the actions of platelet-derived growth factor on mouse fibroblasts.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(3):157-64.
1992: Tamaki T; Kanakura Y; Kuriu A; Ikeda H; Mitsui H; Yagura H; Matsumura I; Druker B; Griffin J D; Kanayama Y
Surface immunoglobulin-mediated signal transduction involves rapid phosphorylation and activation of the protooncogene product Raf-1 in human B-cells.
Cancer research 1992;52(3):566-70.
1992: Held J L; Druker B J; Kohn S R; Byrnes W; Margolis R J
Atypical, nonfatal, transfusion-associated, acute graft-versus-host disease in a patient with Hodgkin's disease.
Journal of the American Academy of Dermatology 1992;26(2 Pt 1):261-2.
1992: Dasgupta J D; Granja C; Druker B; Lin L L; Yunis E J; Relias V
Phospholipase C-gamma 1 association with CD3 structure in T cells.
The Journal of experimental medicine 1992;175(1):285-8.
1991: Kuriu A; Ikeda H; Kanakura Y; Griffin J D; Druker B; Yagura H; Kitayama H; Ishikawa J; Nishiura T; Kanayama Y
Proliferation of human myeloid leukemia cell line associated with the tyrosine-phosphorylation and activation of the proto-oncogene c-kit product.
Blood 1991;78(11):2834-40.
1991: Druker B J; Roberts T M
Generation of a large library of point mutations in polyoma middle T antigen.
Nucleic acids research 1991;19(24):6855-61.
1991: Okuda K; Druker B; Kanakura Y; Koenigsmann M; Griffin J D
Internalization of the granulocyte-macrophage colony-stimulating factor receptor is not required for induction of protein tyrosine phosphorylation in human myeloid cells.
Blood 1991;78(8):1928-35.
1991: Ley S C; Davies A A; Druker B; Crumpton M J
The T cell receptor/CD3 complex and CD2 stimulate the tyrosine phosphorylation of indistinguishable patterns of polypeptides in the human T leukemic cell line Jurkat.
European journal of immunology 1991;21(9):2203-9.
1991: Burgess K E; Odysseos A D; Zalvan C; Druker B J; Anderson P; Schlossman S F; Rudd C E
Biochemical identification of a direct physical interaction between the CD4:p56lck and Ti(TcR)/CD3 complexes.
European journal of immunology 1991;21(7):1663-8.
1991: Longnecker R; Druker B; Roberts T M; Kieff E
An Epstein-Barr virus protein associated with cell growth transformation interacts with a tyrosine kinase.
Journal of virology 1991;65(7):3681-92.
1991: Davis S; Lu M L; Lo S H; Lin S; Butler J A; Druker B J; Roberts T M; An Q; Chen L B
Presence of an SH2 domain in the actin-binding protein tensin.
Science (New York, N.Y.) 1991;252(5006):712-5.
1991: Kanakura Y; Druker B; DiCarlo J; Cannistra S A; Griffin J D
Phorbol 12-myristate 13-acetate inhibits granulocyte-macrophage colony stimulating factor-induced protein tyrosine phosphorylation in a human factor-dependent hematopoietic cell line.
The Journal of biological chemistry 1991;266(1):490-5.
1991: Kanakura Y; Druker B; Wood K W; Mamon H J; Okuda K; Roberts T M; Griffin J D
Granulocyte-macrophage colony-stimulating factor and interleukin-3 induce rapid phosphorylation and activation of the proto-oncogene Raf-1 in a human factor-dependent myeloid cell line.
Blood 1991;77(2):243-8.
1991: Vivier E; Morin P; O'Brien C; Druker B; Schlossman S F; Anderson P
Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing.
Journal of immunology (Baltimore, Md. : 1950) 1991;146(1):206-10.
1990: Druker B J; Ling L E; Cohen B; Roberts T M; Schaffhausen B S
A completely transformation-defective point mutant of polyomavirus middle T antigen which retains full associated phosphatidylinositol kinase activity.
Journal of virology 1990;64(9):4454-61.
1990: Kanakura Y; Druker B; Cannistra S A; Furukawa Y; Torimoto Y; Griffin J D
Signal transduction of the human granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors involves tyrosine phosphorylation of a common set of cytoplasmic proteins.
Blood 1990;76(4):706-15.
1990: Cohen B; Liu Y X; Druker B; Roberts T M; Schaffhausen B S
Characterization of pp85, a target of oncogenes and growth factor receptors.
Molecular and cellular biology 1990;10(6):2909-15.
1990: Epstein R J; Druker B J; Roberts T M; Stiles C D
Modulation of a Mr 175,000 c-neu receptor isoform in G8/DHFR cells by serum starvation.
The Journal of biological chemistry 1990;265(18):10746-51.
1989: Varticovski L; Druker B; Morrison D; Cantley L; Roberts T
The colony stimulating factor-1 receptor associates with and activates phosphatidylinositol-3 kinase.
Nature 1989;342(6250):699-702.
1989: Druker B J; Mamon H J; Roberts T M
Oncogenes, growth factors, and signal transduction.
The New England journal of medicine 1989;321(20):1383-91.
1989: Druker B J; Rosenthal D S; Canellos G P
Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.
Cancer 1989;63(6):1060-4.
1988: Draetta G; Piwnica-Worms H; Morrison D; Druker B; Roberts T; Beach D
Human cdc2 protein kinase is a major cell-cycle regulated tyrosine kinase substrate.
Nature 1988;336(6201):738-44.
1988: Roberts T M; Kaplan D; Morgan W; Keller T; Mamon H; Piwnica-Worms H; Druker B; Cohen B; Schaffhausen B; Whitman M
Tyrosine phosphorylation in signal transduction.
Cold Spring Harbor symposia on quantitative biology 1988;53 Pt 1():161-71.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Brian Druker

Research Profile (preview)

Chemicals & Drugs

Disorders

Phenomena

Living Beings

Physiology

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Brian Druker (preview)

All Publications